The Enterprise Value as of December 2024 (TTM) for C4 Therapeutics, Inc. (CCCC) is 294.04M

According to C4 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 294.04M. This represents a change of -21.67% compared to the average of 375.37M of the last 4 quarters.

C4 Therapeutics, Inc. (CCCC) Historical Enterprise Value (quarterly & annually)

How has CCCC Enterprise Value performed in the past?

The mean historical Enterprise Value of C4 Therapeutics, Inc. over the last ten years is 776.93M. The current 294.04M Enterprise Value has changed 3.68% with respect to the historical average. Over the past ten years (40 quarters), CCCC's Enterprise Value was at its highest in in the September 2021 quarter at 2.03B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

C4 Therapeutics, Inc. (CCCC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of C4 Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

C4 Therapeutics, Inc. (CCCC) Average Enterprise Value

How has CCCC Enterprise Value performed in the past?

The current Enterprise Value of C4 Therapeutics, Inc. (CCCC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

C4 Therapeutics, Inc. (CCCC) Enterprise Value vs. Peers

How is CCCC’s Enterprise Value compared to its peers?

C4 Therapeutics, Inc.’s Enterprise Value is greater than Shattuck Labs, Inc. (12.30M), less than Eliem Therapeutics, Inc. (0), greater than Prelude Therapeutics Incorporated (75.25M), less than Monte Rosa Therapeutics, Inc. (356.78M), greater than Foghorn Therapeutics Inc. (255.47M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than Rezolute, Inc. (248.88M), greater than Century Therapeutics, Inc. (88.73M), less than Edgewise Therapeutics, Inc. (2.80B), less than Mineralys Therapeutics, Inc. (502.94M), less than Cullinan Oncology, Inc. (591.52M), less than Arvinas, Inc. (1.15B), less than Nurix Therapeutics, Inc. (1.34B), less than Kymera Therapeutics, Inc. (2.62B), less than Revolution Medicines, Inc. (7.90B),

Build a custom stock screener for C4 Therapeutics, Inc. (CCCC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like C4 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

C4 Therapeutics, Inc. (CCCC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like C4 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.